SCHEMBL20437157

SCHEMBL20437157

Cc1ccc(S(=O)(=O)n2ccc3c(Oc4ccc(C[C@@H](NC(=O)OC(C)(C)C)C(=O)O)cc4)ccnc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
ITGB3 P05106 1/20 0.45
ITGA2B P08514 1/20 0.45
BCL2 P10415 4/20 0.42
PTPN1 P18031 3/20 0.42
ITGA4 P13612 2/20 0.41
ITGB7 P26010 2/20 0.41
P2RX7 Q99572 2/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
ACE P12821 1/20 0.39
ABCB1 P08183 1/20 0.39
MMP13 P45452 1/20 0.39
SCN9A Q15858 1/20 0.38
KLK7 P49862 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20422562 0.93 MEN1 (0.44) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL20437154 0.93 MEN1 (0.44) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL23799314 0.89 MEN1 (0.48) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL23799313 0.89 MEN1 (0.48) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL20422541 0.88 MEN1 (0.48) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL20422540 0.88 MEN1 (0.48) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL20437155 0.87 ITGB3 (0.44) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL23072642 0.87 ITGB3 (0.44) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL20437156 0.87 ITGB3 (0.44) MEN1POLBKMT2AITGB3ITGA2B
SCHEMBL21593115 0.86 MEN1 (0.40) MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954236-B2 Tyrosine amide derivatives as Rho-Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2021-03-23 US disclosed
EP-3573987-B1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2021-03-10 EP disclosed
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 US disclosed
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954236-B2 Tyrosine amide derivatives as Rho-Kinase inhibitors ROCK1, ROCK2, CIT MEN1 4596/4885POLB 2905/4885KMT2A 1361/4885
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, CIT MEN1 4596/4885POLB 2905/4885KMT2A 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.